Image Source: Unsplash

As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens: Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

A quick look at the share price history over the past twelve months shows that the price is down approximately 21.99%. Here’s a brief look at why the company is undervalued.

Image Source: Google Finance

Key Stats

• Market cap: $97.64 billion
• Enterprise value: $145.04 billion

Operating Earnings

• Operating earnings: $8.17 million

Acquirer’s Multiple

• Acquirer’s multiple: 17.70

Free Cash Flow (TTM)

• Free cash flow: $12.95 billion

FCF/MC Yield Percentage

• FCF/MC yield: 13.26

Shareholder Yield Percentage

• Shareholder yield: 9.00

Other Indicators

• Piotroski F score: 4
• Dividend yield percentage: 4.90
• ROA (five-year average percentage): 9

More By This Author:

American Express Co. DCF Valuation: Is The Stock Undervalued?
McDonald’s Corp Valuation: Is The Stock Undervalued?
Why Unilever PLC Stock Is A Buy